Clinical Research Fellow in Clinical Neuroscience (Institute of Psychiatry, Psychology and Neuroscience – King’s College London)
Dr Ndabezinhle Mazibuko is Clinical Research Fellow in Clinical Neuroscience (Institute of Psychiatry, Psychology and Neuroscience – King’s College London) whose work includes clinical trial design, management and data analysis with respect to pharmacological and neuro-imaging studies in both the academic and industry sectors.
His academic role includes medical student tutoring and periodic lectures. Prior to that he was an Acute Stroke and Neurology Registrar at King’s College Hospital and has several years’ experience as a clinician in varied disciplines within the NHS in addition to clinical experience in Australia (where he trained) and also in Africa.
He has a keen interest in Public Health Medicine and now also assists The Health Services and Population Research Department at King’s College London with data analysis with a view to policy creation and implementation for Non Communicable Diseases.
Since October 2014 he has clinically reviewed patients through the Care Oncology Clinic, implementing the protocol for the clinic. The medication regime that the clinic uses has its foundation in metabolic treatment with which Dr Mazibuko has extensive clinical experience.
Barts Health NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK
Dr Agrawal qualified at the University of Bristol, UK, trained at The Royal Marsden Cancer Hospital, London, UK, and was awarded his PhD in Tumour Immunology from the University of Paris, France. He is Director of the Stem Cell Laboratory of the Barts Health NHS Trust, and has an interest in diagnostic immunophenotyping. He was a winner of the NHS Innovator Award in 2006 for the introduction of new diagnostic tests for the diagnosis of human leukaemias.
Dr Agrawal’s clinical activities stretch across all areas of haematological cancers, ranging from intensive chemotherapy for acute leukaemia to outpatient non-intensive chemo-immunotherapy for lymphoid diseases, particularly chronic lymphocytic leukaemia (CLL) and other lymphoid malignancies. Dr Agrawal has designed, funded, and implemented studies on myelodysplastic syndromes, invasive aspergillosis and CLL. A former member of the UK CLL Trials Committee, he is a trustee for CLLSA (the patient-led support organisation for patients in the UK with CLL), as well as a NICE reviewer and the haemato-oncology representative on the UK IVIg initiative. He is a member of the European group (ECIL) for guidelines for infection management.
Dr Agrawal’s research activities are focussed on CLL biology and developing novel approaches to treating this incurable disease; and improving patient experience with the development of the “remote patient monitoring programme”, which allows specialist follow-up without requiring attendance at the hospital. His current activities in the field of invasive fungal disease include a diagnostic study of high-risk haematology patients looking at improved and earlier diagnosis. He is also working to develop clinical guidelines and integrated care pathways for managing infection in the high-risk haemato-oncology setting and to promote best practice and highlight new developments through educational meetings.
Dr Padman Vamadevan undertook a Natural Sciences degree at Queens’ College, Cambridge, and subsequently completed his medical degree on the fast-track programme at Guy’s, King’s and St Thomas’ School of Medicine in London. He subsequently secured an Academic Foundation training post at Guy’s & St Thomas’ Hospitals, during which he was seconded to Quintiles Drug Research Unit where he was involved in trial design and management and data analysis.
Following this, he was appointed as an Academic Clinical Fellow in Clinical Pharmacology at St George’s Hospital and during this period, published multiple peer-reviewed papers, whilst also receiving a travel fellowship to speak at the European Respiratory Society congress. Subsequently, he has taken up a variety of Haematological and Oncological posts at a variety of leading cancer institutions in London, which have afforded him significant relevant clinical experiance.
He has worked at the Care Oncology Clinic for over two years, and his familiarity with Biochemistry, Clinical Pharmacology, Clinical Research Studies and Oncology are consistent with the academic lineages that underpin the metabolic treatments offered by the clinic.
Dr Hariharan Kuhan is one of the newest members of the team. He completed his undergraduate medical training at Imperial College London where he graduated with a BSc in Surgery and Anaesthesia. He performed his foundation and core medical training in London, working at hospitals such as St Mary’s and St Bartholomew’s. He has gained significant experience working in Medical Oncology at centres of excellence such as St Bartholomew’s, University College London and Royal Marsden Hospitals.
Following a research fellowship at Barts Cancer Institute where he gained laboratory experience targeting metabolic pathways in cancer stem cells and circulating tumour cells, he went on to develop translational phase 1 trials based on his pre-clinical work. He attained a clinical fellow role working in an early phase trials unit, the Sarah Cannon Research Institute UK, where he was lead sub-investigator for a variety of solid tumour trials.
Dr Kuhan continues to play an active role in clinical research and drug development. His strong background in mainstream oncology coupled with his trials experience and research work in metabolic targeting make him an excellent fit with the existing medical team at the clinic.